United States · 
What does OrbiMed invest in?
OrbiMed invests most often at Series B and Series A (52% of the rounds on record), in sectors such as Healthcare, Medtech and Tech-enabled Health.
OrbiMed highlights
- 01
55 cheques in the last 12 months
- 02
Mostly Series B and Series A: 52% of its rounds
- 03
Sole investor in 32 rounds, median $30M
- 04
23 exits from the portfolio
What they do
We have been investing globally for over 25 years across the healthcare industry: from early-stage private companies to large multinational corporations.From their own website
- Type
- Private equity (from a list, unverified)
- Cheque size
- $1.0M – $75M as they say
- Stages
- SeedSeries ASeries BGrowthPre-IPO
- Sectors
- HealthcareMedtechTech-enabled Health
- Based in
- New York, United States
- Cold pitches
- Not stated
The record
Every round we can evidence, newest first447 appearances
- 2026
42 rounds
- Oct
- Oct
- Sept
- Sept
- Sept
- Sept
- Jul
- Jul
- Jul
- Jul
- Jul
- Jun
- Jun
- Jun
- Jun
- Jun
- May
- May
- May
- May
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Apr
- Mar
- Mar
- Mar
- Mar
- Mar
- Feb
- Feb
- Jan
- Jan
- Jan
An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.
The team
Named by the firm itself, on a filing, its Form ADV or its company registration24 named
AMAlexander Matthew CooperGeneral CounseliForm ADV
BKBarbra KocsisManager of the AdministratoriFiling they signed
BLBrendan LakeRelated person is managing member of the general partneriFiling they signed
BHBrian H. BurkholderDirectoriFiling they signed
BWBrian WoldowManager of the AdministratoriFiling they signed
CSC. Scotland StevensMember of the Managing Member of the General PartneriFiling they signed
CLCarl Lee GordonMember of the Managing Member of the General PartneriFiling they signed
CSCharles Scotland StevensMemberiForm ADV
CRColleen RuschDirector of the General PartneriFiling they signed
DSDavid Scotland BonitaMember of the Managing Member of the General PartneriFiling they signed
DGDavid G. WangDirector of the GPLTDiFiling they signed
DMDeann MorganDirector of the General PartneriFiling they signed
DSDevesh SaksenaManager of the AdministratoriFiling they signed
DWDouglas W. CoonChief Compliance OfficeriForm ADV
ELEdward L. Truitt, Jr.Executive OfficeriFiling they signed
EDEvan D. SotiriouDirectoriFiling they signed
GCGeoffrey Che-Chang HsuMember of the Managing Member of the General PartneriFiling they signed
GBGraham B.R. CollisDirectoriFiling they signed
JCJames CostabileManager of the Managing TrusteeiFiling they signed
JMJeff McGoeyDirector of the General PartneriFiling they signed
JLJohn LealeManager of the AdministratoriFiling they signed
JTJonathan T. SilversteinMember of the Managing Member of the General PartneriFiling they signed
KGKeith GlenfieldManager of the Managing TrusteeiFiling they signed
LRLeslie RossManager of the AdministratoriFiling they signed
We also hold 98 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.
What the register says
From the firm's own filings with the SEC, which it must file accurately by law
$21Bassets it managesOct 2026
10+funds on filenumbered funds in its name
Registeredinvestment adviserfull reporting to the SEC
- Legal name
- Orbimed Advisors LLC
- SEC number
- CRD 118608
Funds on its Form ADV
20 private funds, $15B in gross assets · filed Mar 2024
Fund meets the definition of 11Hedge 6Private equity 3
- OrbiMed Private Investments IX, L.P.Fund meets the definition of292 investors$1.9B
- OrbiMed ASIA Partners III, L.P.Fund meets the definition of117 investors$1.8B
- OrbiMed Private Investments VIII, L.P.Fund meets the definition of186 investors$1.7B
- OrbiMed Royalty & Credit Opportunities IV, L.P.Private equity405 investors$1.5B
- OrbiMed Private Investments VII, L.P.Fund meets the definition of145 investors$1.4B
- OrbiMed Private Investments VI, L.P.Fund meets the definition of140 investors$1.0B
- OrbiMed Royalty & Credit Opportunities III, L.P.Private equity113 investors$968M
- OrbiMed ASIA Partners IV, L.P.Fund meets the definition of132 investors$933M
- OrbiMed Partners Master Fund LimitedHedge195 investors$775M
- OrbiMed ASIA Partners V, L.P.Fund meets the definition of95 investors$733M
And 10 more on the filing.
Who backs their funds
2 LPs on record in OrbiMed's funds
- Committed
- $545M
- Funds
- 8
- Vintages
- 2009 to 2025
The institutions that put money into its funds, which the firm then invests in companies.Source: the pension's own report, latest Sept 2025.
- California State Teachers Retirement System7 funds$405M
Fund Vintage Committed OrbiMed Royalty Credit Opps V 2025 $75M OrbiMed Private Investments IX 2022 $75M OrbiMed Royalty Credit Opps IV 2022 $75M OrbiMed Private Investments VIII 2020 $50M OrbiMed Royalty & Credit Opportunities III 2019 $50M OrbiMed Private Investments V 2013 $40M OrbiMed Private Investments IV 2010 $40M 
Oregon Public Employees Retirement Fund3 funds$140MFund Vintage Committed OrbiMed Private Investments VI 2015 $60M OrbiMed Private Investments V 2013 $40M OrbiMed Private Investments IV 2009 $40M
What they claim to have backed
From their own portfolio page (on their website)
21 of 60 we have independently watched raise
worldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldworldand 100 more
Weaker than a round we watched, stronger than a list somebody sold us. A firm is far less willing to put a company on its own site that it never funded.
Exits from the portfolio
Companies it backed that were later bought or listed23 in all
Cardioxyl PharmaceuticalsBought by Bristol-Myers Squibb$2.0BNov 2015
CardiAQ Valve TechnologiesBought by Edwards Lifesciences$350MJul 2015
Auxilium PharmaceuticalsBought by Endo Health Solutions$2.6BOct 2014
Ambit BiosciencesBought by Daiichi Sankyo$410MSept 2014
Civitas TherapeuticsBought by Acorda Therapeutics$525MSept 2014
Seragon PharmaceuticalsBought by Genentech$725MJul 2014
Rempex PharmaceuticalsBought by The Medicines Company$464MDec 2013
Aragon PharmaceuticalsBought by Johnson & Johnson$1.0BJun 2013
ACADIA PharmaceuticalsListed$115MMay 2013
Vessix VascularBought by Boston Scientific$300MNov 2012
EUSA PharmaBought by Jazz Pharmaceuticals$650MApr 2012
SuperDimensionBought by Covidien$300MMar 2012
Enobia PharmaBought by Alexion PharmaceuticalsUndisclosedDec 2011
Innovative Spinal TechnologiesBought by Theken Spine$9.3MSept 2009
Arius ResearchBought by Roche$143MJul 2008
SGX PharmaceuticalsBought by Eli Lilly$66MJul 2008
CryoCorBought by Boston ScientificUndisclosedMay 2008
EUSA PharmaBought by EUSA Pharma$23MMar 2008
Auxilium PharmaceuticalsListedUndisclosedDec 2007
The latest 20 here. An exit counts when it came after the firm's first round in the company. From historical deal records.